Phenotypic Analysis of Tumor Tissue-Infiltrating Lymphocytes in Tumor Microenvironment of Bladder Cancer and Upper Urinary Tract Carcinoma.


Journal

Clinical genitourinary cancer
ISSN: 1938-0682
Titre abrégé: Clin Genitourin Cancer
Pays: United States
ID NLM: 101260955

Informations de publication

Date de publication:
04 2019
Historique:
received: 02 04 2018
revised: 26 10 2018
accepted: 11 11 2018
pubmed: 18 12 2018
medline: 25 2 2020
entrez: 18 12 2018
Statut: ppublish

Résumé

There are no previous reports directly evaluating immunologic conditions in tumor microenvironment including both bladder cancer (BCa) and upper urinary tract carcinoma (UTUC). In this study, we aimed to clarify the difference of immunity status and its clinical significance depending on the tumor site in urothelial carcinoma. Tumor tissue-infiltrating lymphocytes were extracted from 70 urothelial cancer patients who underwent surgical resection (52 cases of BCa and 18 cases of UTUC). The immunologic classification was established by unsupervised clustering analysis according to the expression ratio of 9 extracellular surface markers measured by flow cytometry, and we examined the relationship between immunologic classification and clinical importance such as pathologic status and prognosis (progression-free survival and cancer-specific survival). The immunologic condition was classified into 2 groups. Group 1 (n = 41) comprised the CD4 T-cell-dominant group and group 2 (n = 29) the immunologically activated group. This immunologic classification was significantly correlated with tumor grade (P = .020) but not tumor location in multivariate analysis. In invasive BCa patients (n = 33), progression-free survival and cancer-specific survival of group 2 were significantly worse than those of group 1 (P = .021 and P = .022, respectively), while there was no significant difference between groups 1 and 2 in patients with invasive UTUC (n = 17). Although there was no difference in the local immunologic condition of urothelial carcinoma between BCa and UTUC, its significance as a prognostic predictor might vary depending on tumor site.

Sections du résumé

BACKGROUND
There are no previous reports directly evaluating immunologic conditions in tumor microenvironment including both bladder cancer (BCa) and upper urinary tract carcinoma (UTUC). In this study, we aimed to clarify the difference of immunity status and its clinical significance depending on the tumor site in urothelial carcinoma.
PATIENTS AND METHODS
Tumor tissue-infiltrating lymphocytes were extracted from 70 urothelial cancer patients who underwent surgical resection (52 cases of BCa and 18 cases of UTUC). The immunologic classification was established by unsupervised clustering analysis according to the expression ratio of 9 extracellular surface markers measured by flow cytometry, and we examined the relationship between immunologic classification and clinical importance such as pathologic status and prognosis (progression-free survival and cancer-specific survival).
RESULTS
The immunologic condition was classified into 2 groups. Group 1 (n = 41) comprised the CD4 T-cell-dominant group and group 2 (n = 29) the immunologically activated group. This immunologic classification was significantly correlated with tumor grade (P = .020) but not tumor location in multivariate analysis. In invasive BCa patients (n = 33), progression-free survival and cancer-specific survival of group 2 were significantly worse than those of group 1 (P = .021 and P = .022, respectively), while there was no significant difference between groups 1 and 2 in patients with invasive UTUC (n = 17).
CONCLUSION
Although there was no difference in the local immunologic condition of urothelial carcinoma between BCa and UTUC, its significance as a prognostic predictor might vary depending on tumor site.

Identifiants

pubmed: 30555025
pii: S1558-7673(18)30245-3
doi: 10.1016/j.clgc.2018.11.004
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

114-124

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Atsunari Kawashima (A)

Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan. Electronic address: kawashima@uro.med.osaka-u.ac.jp.

Takayuki Kanazawa (T)

Department of Clinical Research in Tumor Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan; Drug Discovery & Disease Research Laboratory, Shionogi & Co Ltd, Toyonaka, Japan.

Kentaro Jingushi (K)

Department of Urological Immuno-oncology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Taigo Kato (T)

Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan; Department of Urological Immuno-oncology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Takeshi Ujike (T)

Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Akira Nagahara (A)

Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Kazutoshi Fujita (K)

Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Akiko Morimoto-Okazawa (A)

Department of Clinical Research in Tumor Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Kota Iwahori (K)

Department of Clinical Research in Tumor Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Motohide Uemura (M)

Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan; Department of Urological Immuno-oncology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Ryoichi Imamura (R)

Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Hisashi Wada (H)

Department of Clinical Research in Tumor Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Norio Nonomura (N)

Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH